sorafenib-sensitive PDGFR mutants [plasma membrane]

Stable Identifier
R-HSA-9673717
Type
Set [DefinedSet]
Species
Homo sapiens
Compartment
plasma membrane
Locations in the PathwayBrowser
Expand all
Literature References
PubMed ID Title Journal Year
31723821 FIP1L1-PDGFRα p.T674I-D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1-PDGFRα Positive Leukemia

Smits, S, Appleby, N, Conneally, E, Vandenberghe, P, Michaux, L, Lierman, E

Hemasphere 2019
22665524 Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors

Fletcher, JA, Mariño-Enríquez, A, Heinrich, MC, Donsky, RS, Presnell, A, Griffith, DJ, McKinley, A, Liang, CW, Patterson, J, Taguchi, T

Mol. Cancer Ther. 2012
16645167 Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

Marynen, P, Boogaerts, M, Folens, C, Vandenberghe, P, Mentens, N, Scheers, W, Lierman, E, Cools, J, Van Miegroet, H, Stover, EH

Blood 2006
Participants
members
Participates
as a member of
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!